Top-News

Sio Gene Therapies Inc. News

Aktie
WKN:  A2QHKW ISIN:  US8293991043 US-Symbol:  SIOX
Keine aktuellen Kursdaten verfügbar
Handeln Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Aktienanzahl *
73,21 Mio.
Marktkapitalisierung *
31,99 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 17.01.2024

Sio Gene Therapies Inc. News

13.06.17 - PR Newswire
Axovant Sciences Announces Fiscal Year-End Financial Results and Corporate Updates
Axovant Sciences Announces Fiscal Year-End Financial Results and Corporate Updates PR Newswire
06.06.17 - PR Newswire
Axovant Announces Changes to Board of Directors
Axovant Announces Changes to Board of Directors PR Newswire
06.06.17 - PR Newswire
Axovant Strengthens Executive Team with Key Management Appointments
Axovant Strengthens Executive Team with Key Management Appointments Accomplished Industry Leaders Join Recently Appointed CEO David Hung and COO Marion McCourt PR ...
31.05.17 - PR Newswire
Axovant Sciences to Present at Upcoming Investor Conferences
Axovant Sciences to Present at Upcoming Investor Conferences PR Newswire
17.04.17 - PR Newswire
Axovant Sciences Ltd. Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Common Shares
Axovant Sciences Ltd. Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Common Shares PR Newswire
10.04.17 - PR Newswire
Axovant Sciences Announces Appointment of Dr. David Hung as Chief Executive Officer and Expansion of Board of Directors
Axovant Sciences Announces Appointment of Dr. David Hung as Chief Executive Officer and Expansion of Board of Directors - David Hung, MD, founder and former CEO of ...
21.03.17 - PR Newswire
Axovant Sciences to Present at Upcoming Scientific Meetings
Axovant Sciences to Present at Upcoming Scientific Meetings PR Newswire
20.03.17 - PR Newswire
Axovant Sciences Announces Presentation Time Change at Oppenheimer Healthcare Conference
Axovant Sciences Announces Presentation Time Change at Oppenheimer Healthcare Conference PR Newswire
27.02.17 - PR Newswire
Axovant Sciences to Present at Upcoming Investor Conferences
Axovant Sciences to Present at Upcoming Investor Conferences PR Newswire
14.02.17 - PR Newswire
Axovant Sciences Announces Dementia Pipeline Updates and Reports Financial Results for the Third Fiscal Quarter and Nine Months Ended December 31, 2016
Axovant Sciences Announces Dementia Pipeline Updates and Reports Financial Results for the Third Fiscal Quarter and Nine Months Ended December 31, 2016 PR Newswire
13.02.17 - PR Newswire
Axovant Sciences Announces Preliminary Results from Interim Analysis of Phase 2 Study Testing Investigational Drug Nelotanserin in Lewy Body Dementia Patients
Axovant Sciences Announces Preliminary Results from Interim Analysis of Phase 2 Study Testing Investigational Drug Nelotanserin in Lewy Body Dementia Patients -- Beneficial ...
03.02.17 - PR Newswire
Axovant Sciences Announces $55.0 Million Venture Debt Financing from Hercules Capital
Axovant Sciences Announces $55.0 Million Venture Debt Financing from Hercules Capital PR Newswire
25.01.17 - PR Newswire
Axovant Sciences to Present at Upcoming Investor Conferences
Axovant Sciences to Present at Upcoming Investor Conferences PR Newswire
09.01.17 - PR Newswire
Axovant Sciences Announces Pipeline Program Updates and Presentation at 35th Annual J.P. Morgan Conference
Axovant Sciences Announces Pipeline Program Updates and Presentation at 35th Annual J.P. Morgan Conference - Recruitment in MINDSET study completed - Intepirdine TQT ...
09.12.16 - PR Newswire
Axovant Unveils New Data Analysis Showing Addition of Intepirdine to Standard Therapy May Help People with Alzheimer's Disease Maintain Independence Longer
Axovant Unveils New Data Analysis Showing Addition of Intepirdine to Standard Therapy May Help People with Alzheimer's Disease Maintain Independence Longer PR Newswire
05.12.16 - PR Newswire
Axovant to Present Patient Function and Independence Data Analyses from Phase 2b Study of Investigational Treatment Intepirdine in Alzheimer's Disease at CTAD 2016
Axovant to Present Patient Function and Independence Data Analyses from Phase 2b Study of Investigational Treatment Intepirdine in Alzheimer's Disease at CTAD 2016 PR Newswire
23.11.16 - Börse Online
Wall Street: Dow Jones startet vor Thanksgiving kaum verändert
Nach der jüngsten Kursrally mit neuen Rekordständen sind die US-​Aktienmärkte am Mittwoch verhalten in den Handel gestartet. Börsianer stellten sich auf ein ruhiges Geschäft ein ...
07.11.16 - PR Newswire
Axovant Sciences Announces Dementia Pipeline Updates and Reports Financial Results for the Second Fiscal Quarter and First Half Ended September 30, 2016
Axovant Sciences Announces Dementia Pipeline Updates and Reports Financial Results for the Second Fiscal Quarter and First Half Ended September 30, 2016 - Target patient ...
01.11.16 - PR Newswire
Axovant Sciences to Present at Upcoming Investor Conferences
Axovant Sciences to Present at Upcoming Investor Conferences PR Newswire
19.10.16 - PR Newswire
Patrick Machado Joins Board of Directors of Roivant Sciences
Patrick Machado Joins Board of Directors of Roivant Sciences PR Newswire

Newssuche

Videos

17.05.24 -2,19%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »